Quality assessment of randomized controlled trials of compound traditional Chinese medicine prescriptions in treatment of nonalcoholic steatohepatitis in 2018—2023
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 12
Abstract
[Objective] To assess the quality of randomized controlled trials （RCTs） of compound traditional Chinese medicine （TCM） prescriptions in the treatment of nonalcoholic steatohepatitis （NASH）， and to provide recommendations for standardizing the design and reporting of RCTs in this field. [Methods] Databases such as PubMed， Web of Science， Embase， the Cochrane Library， CNKI， VIP， and Wanfang Data were searched for RCTs of compound TCM prescriptions in the treatment of NASH published from January 1， 2018 to December 31， 2023， and the articles were screened and assessed based on the Cochrane risk-of-bias assessment tool （RoB 2）， the unified standard for clinical trial reporting （CONSORT 2010）， and CONSORT-CHM Formulas 2017 for compound TCM prescriptions. [Results] A total of 45 articles were finally included， and most of these studies were rated as high-risk bias by RoB 2.0. The analysis based on the CONSORT control checklist showed a relatively low reporting rate for most of the key items regarding the quality of RCT studies. [Conclusion] A relatively large risk of bias is observed in the clinical studies on compound TCM prescriptions in the treatment of NASH published in the past six years， which may lead to the poor quality of reporting and evidence. It is suggested that the top-level design of clinical studies should be taken seriously in addition to investigating the advantages of TCM， so as to improve the quality of clinical studies.
Authors and Affiliations
Weiwei YAO, Ruimin JIAO, Kejia LIU, Shuai XU, Li LI, Hong YOU, Jingjie ZHAO
Keywords
Related Articles
- EP ID EP753953
- DOI 10.12449/JCH241210
- Views 24
- Downloads 0
Influencing factors for rebleeding after endoscopic therapy in patients with liver cirrhosis receiving secondary prevention of gastroesophageal varices
[Objective] To investigate the influencing factors for rebleeding after endoscopic therapy and the effect of the number of sequential treatment sessions on postoperative rebleeding in patients with liver cirrhosis receiv...
Research advances of noninvasive diagnosis of fibrotic non-alcoholic steatohepatitis
A subset of patients with non-alcoholic fatty liver disease （NAFLD） can progress to nonalcoholic steatohepatitis （NASH）. When NASH reaches a fibrosis degree of F≥2 and a NAS score of≥4， this stage of NASH is referre...
Value of modified albumin-bilirubin grade in predicting the prognosis of patients with Child-Pugh class A unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs
[Objective] To investigate the ability of the modified albumin-bilirubin （mALBI） grade in predicting the prognosis of patients with Child-Pugh A unresectable hepatocellular carcinoma （uHCC） after transcatheter arteri...
Advances in the application of endoscopic ultrasonography in the diagnosis and treatment of cholangiocarcinoma
Endoscopic ultrasonography （EUS） can not only directly observe the morphology of the lumens of the digestive tract through the endoscope， but also perform real-time dynamic ultrasound scanning to obtain the layers of...
Risk factors for the prognosis of elderly patients with hepatitis B virus-related acute-on-chronic liver failure and construction of a nomogram model for risk prediction
[Objective] To investigate the clinical features of elderly patients with hepatitis B virus-related acute-on-chronic liver failure （HBV-ACLF） and the risk factors affecting the short-term prognosis of patients. [Method...